Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 7Neoplasms 2Lung Neoplasms 2Colonic Neoplasms 2Carcinoma, Hepatocellular 2Stomach Neoplasms 1Rectal Neoplasms 1Pancreatic Ductal Adenocarcinoma 1Pancreatic Cancer Metastatic 1Ovarian Neoplasms 1Neoplasm Metastasis 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1Breast Neoplasms 1Biliary Tract Neoplasms 1Bile Duct Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Gemcitabine 3folfirinox 2Oxaliplatin 2Irinotecan 2toripalimab 1surufatinib 1sintilimab 1devimistat 1chloroquine diphosphate 1balstilimab 1Taxes 1Paclitaxel 1Leucovorin 1Injections 1Immune Checkpoint Inhibitors 1Drug Therapy 1Cisplatin 1Chloroquine 1Celecoxib 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Cancer Metastatic × devimistat × Gastrointestinal × Clear all
NCT03504423 2023-01-03

Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas

Cornerstone Pharmaceuticals

Phase 3 Completed
528 enrolled 11 charts
Gastrointestinal

Pancreatic Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡